Lv6
2268 积分 2022-07-12 加入
OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial
1个月前
已完结
Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection
1个月前
已完结
Integrated pharmacokinetic-pharmacodynamic and agent-based modelling in drug development: Current status and future perspectives
4个月前
已完结
The targeted protein degradation landscape
5个月前
已完结
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
5个月前
已完结
Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis
5个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
6个月前
已完结
The present and future of bispecific antibodies for cancer therapy
6个月前
已完结
Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer
7个月前
已完结
Visual predictive check of longitudinal models and dropout
7个月前
已完结
皖公网安备34019202002308
